Pfizer (NYSE:PFE) hasn't been bashful about playing up the prospects for its coronavirus vaccine candidate, BNT162b2, co-developed with BioNTech (NASDAQ:BNTX). The company even predicted that it would be able to submit its investigational vaccine for regulatory review as early as October 2020. Few, if any, of Pfizer's rivals have been so publicly confident.
But Pfizer hasn't attempted to draw attention to everything it's doing on the COVID-19 vaccine front. On the contrary, the big drugmaker is making a stealthy move that could cement its position as the clear leader in the coronavirus vaccine race.